Predstanormix Duo: A New Domestic Combination Drug for Treating Lower Urinary Tract Dysfunction Symptoms Associated with BPH
June 2025
in “
Experimental and Сlinical Urology
”
Studysummary This research found that the new combination drug Predstanormix Duo, with dutasteride and tamsulosin, is bioequivalent to established treatments for benign prostatic hyperplasia, showing similar pharmacokinetics and safety, potentially improving treatment availability and adherence in high-risk patients. Our plain-language summary of this paper — not a Tressless recommendation.
The study introduces Predstanormix Duo, a new domestic combination drug for treating lower urinary tract dysfunction symptoms associated with benign prostatic hyperplasia (BPH). This drug combines dutasteride and tamsulosin in modified-release capsules and has been shown to be bioequivalent to existing treatments. The research involved three groups of comparative clinical studies, demonstrating the drug's high safety and bioequivalence with calculated 90% confidence intervals for pharmacokinetic parameters. Predstanormix Duo is expected to enhance treatment accessibility, improve patient adherence, and offer economic benefits for long-term use.
